TrialBMC gastroenterology2016

Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.

Carol A Burke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.